ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 368

Serum C1M Level Predicts Disease Progression and Early Treatment Efficacy in Rheumatoid Arthritis

Anne C. Bay-Jensen1, Anne Sofie Siebuhr2, Inger Byrjalsen3, Claus Christiansen3 and Morten Asser Karsdal1, 1Nordic Bioscience, Biomarkers and Research, Herlev, Denmark, 2Rheumatology, Nordic Bioscience, Biomarkers and Research, Herlev, Denmark, 3Nordic Bioscience, Herlev, Denmark

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: Biomarkers, Personalized Medicine, Rheumatoid arthritis (RA), tocilizumab and treatment

  • Tweet
  • Email
  • Print
Session Information

Title: Rheumatoid Arthritis - Clinical Aspects: Novel Biomarkers and Other Measurements of Disease Activity

Session Type: Abstract Submissions (ACR)

Background/Purpose: Rheumatoid arthritis (RA) is partly characterized by joint destruction. Personalized health care is needed in RA to enable i) prediction of those patients that will progress most rapidly and in most need of aggressive intervention, and ii) prediction of those that will respond to a given treatment and those that will not, and thereby limiting the cases of serious side effects. Serum C1M is specific measure of connective tissue degradation, which originates from the down-stream signaling pathways of inflammatory cytokines IL-6, IL-1 and TNFα. The aims of the study were to investigate: i) whether levels of C1M could predict who would structurally progress over 1-year, ii) to which level C1M was suppressed by tocilizumab (TCZ), and iii) whether baseline levels or early changes of C1M could predict responders to TCZ either on disease activity or structural protection.

Methods: The LITHE Biomarker study (NCT00106535) was a 1-year phase III, double-blind, placebo-controlled, parallel group study of TCZ 4mg/kg+MTX (n=200), 8mg/kg+MTX (n=186) or PBO+MTX (n=199) in patients with moderate-severe active RA, but MTX-IR. All patients had radiographically confirmed joint erosion at baseline. Fasting serum was collected at baseline and week 4, 16, 24 and 52 weeks. Patients who failed to respond to treatment (≤ 20% improvement in both swollen and tender joint counts) at week 16 were designated early non-responders. Radiographs (total Genant-modified Sharp scoring system (mTSS) and joint space narrowing (JSN)) and DAS28  were obtained at baseline, week 24 and 52. The study was approved by ethical committees at each participating institution. All patients provided written informed consent. C1M was measured in samples taken at baseline and week 4. Spearman’s ranked correlation was done on baseline level and 4-week change of C1M, age, body mass index (BMI), disease duration, DAS28, JSN and mTSS weeks 24 and 52. Multiple regression analysis was performed on log-transformed data for delta structural progression (JSN and mTSS) and C1M, adjusted for age, BMI, disease duration, baseline CRP and radiography.

Results: At baseline, C1M was significantly correlated to DAS28 (ρ=0.25, P<0.0001), mTSS (ρ=0.14, P=0.0006), and JSN (ρ=0.12, P=0.0056). C1M was at correlated to change in JSN and mTSS (p<0.0001). The level of C1M was at the level of the placebo group when treated with 4mg/kg TCZ, whereas the 8mg/kg TCZ suppressed the level by 49.2% lower than at baseline, p<0.0001). The level of C1M remained at a significantly lower level in the 8 mg/kg TCZ + MTX than in PBO group throughout the study (p<0.0001). The difference in C1M between early responders and non-responders when treated with 8 mg/kg were significant (AUC 0.71, p=0.0010). C1M was not correlated to age, BMI or disease duration.

Conclusion: Baseline C1M levels correlated to worsening joint structure over one year, demonstrating this as the first structural progression marker for RA. Early changes in C1M were associated with structural efficacy. These data in combination with other technologies may be a part of the identification of those RA patients that are in most need of aggressive treatment, and the monitoring of these patients.


Disclosure:

A. C. Bay-Jensen,

Nordic Bioscience Holding A/S,

1,

Nordic Bioscience Diagnostic,

3;

A. S. Siebuhr,

Nordic Bioscience A/S,

3;

I. Byrjalsen,

Nordic Bioscience Diagnostic,

3;

C. Christiansen,

Nordic Bioscience Diagnostic,

1;

M. A. Karsdal,

Nordic Bioscience Diagnostic,

3.

  • Tweet
  • Email
  • Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/serum-c1m-level-predicts-disease-progression-and-early-treatment-efficacy-in-rheumatoid-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology